HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
October 18, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
October 09, 2023 08:04 ET
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Propulsion of Hepatitis B Virus Infection Clinical Trial Pipeline as Novel and Extensive 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
June 06, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, June 06, 2023 (GLOBE NEWSWIRE) -- Propulsion of Hepatitis B Virus Infection Clinical Trial Pipeline as Novel and Extensive 90+ Therapies Likely to Enter in the Treatment Domain |...
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
March 16, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
June 08, 2022 07:34 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been...
Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference
March 05, 2018 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, March 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference
February 05, 2018 07:05 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences to Present at the Jefferies London Healthcare Conference
November 08, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences Announces 2017 AASLD Presentations
October 02, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations
February 16, 2017 07:05 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...